The media and social networks echoed yesterday excellent news from the Hospital Clínic of Barcelona, announcing the preliminary results of their newly implemented Artificial Intelligence (AI) based software to treat COVID-19 patients
The immune system is amazingly complex, precise and synchronised to deliver effective responses against most health insults. Likewise, medical challenges need to be faced with a multidisciplinary, coordinated and target-specific approach.
In 2016, AQuAS (Catalan Agency for Health Quality and Evaluation), defined indicators used to evaluate the clinical and healthcare quality as a measurement instrument used to evaluate or measure specific aspects of the quality of care.
The R&D response to the SARS-CoV-2 outbreak has been massive, promoted by unprecedented funding to support innovative solutions to fight the COVID-19 pandemic.
Clinical research is essential in contemporary medicine. It is a source of knowledge to improve healthcare, as it which is based on evidence. It helps to evaluate new drugs and , therapies. It is a a necessary step to test new assets but also to develop and gather advice from the best key opinion leaders.
HiTT celebrates that Barcelona Activa recognizes Qbeast with an award for the best project of high technological impact and Hospital Vall d’Hebron obtains more than 1M€ benefit from the exploitation of a patent license.
Health Innovation Technology Transfer (HITT) is working on the development of an European project in Big Data tools. This project tries to understand the needs of the professionals that use Big Data tools in its analytical procedures.
Dr. Sola Morales will discuss about the topic that in 1999, the EU enacted legislation to foster the introduction of new Orphan Medicinal Products (OMP) into the market. To date only partial evaluations of the success of this legislation have been made, so this analysis investigates the outcomes of the OMP legislation from a broader perspective.